Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888600 | 0.88 | AKR1C3 (0.39) | RAB9ANPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17899158 | 0.84 | AKR1C3 (0.41) | RAB9ANPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17899152 | 0.83 | AKR1C3 (0.38) | RAB9ANPC1MEN1KMT2AAKR1C3 | |
| SCHEMBL17888618 | 0.81 | AKR1C3 (0.45) | RAB9AMEN1KMT2AAKR1C3AKR1C2 | |
| SCHEMBL17931447 | 0.80 | MAPT (0.40) | RAB9AL3MBTL1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL17888611 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4E | |
| SCHEMBL23190672 | 0.78 | SPIN1 (0.38) | AKR1C3AKR1C2MAPTSPIN1 | |
| SCHEMBL17888653 | 0.76 | AKR1C3 (0.39) | AKR1C3AKR1C2ALDH1A1MAPTKDM4E | |
| SCHEMBL17888547 | 0.75 | MEN1 (0.38) | RAB9AMEN1KMT2AAKR1C3AKR1C2 | |
| SCHEMBL17888616 | 0.75 | CETP (0.41) | AKR1C3AKR1C2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| EP-3607944-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | RAB9A 983/4885NPC1 307/4885MEN1 1343/4885 |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | CCNI, CDK9, CDK8 | RAB9A 1635/4885NPC1 4421/4885MEN1 2538/4885 |
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | CCNI, CDK9, CDKN1A | RAB9A 1734/4885NPC1 4388/4885MEN1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.